View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Hamilton Faber
  • Hamilton Faber

Model update

This report contains forecasts updated for reported Q218 results. Neither our financial nor PSU estimates are materially changed and we remain Overweight with a 12m PT of $365.

Kunaal Malde ... (+2)
  • Kunaal Malde
  • CFA

V/MA: strong core, adjacencies more competitive

V/MA remain core long term holdings with secular cash to card tailwinds driving strong growth long term, supported by developments such as contactless. Valuation remains reasonable, although newer growth areas such as B2B face greater competition. We remain Overweight V/MA, raise our price targets to $173 and $250 respectively and currently favour V which trades on a PE of 28x, three turns lower than MA.

John Heagerty ... (+3)
  • John Heagerty
  • Nadja Heini
  • CFA

Banks: Trading update and 3Q18 preview

Market volatility has moderated significantly since the beginning of the year, ceasing to be a tailwind for the banks' trading revenues in 3Q18. Despite the strong IB pipelines (announced M&A is up 40% YTD), fee pools have been affected by timing issues and are down 15-20% across the industry for the current quarter. Medium term, the outlook remains positive thanks to improving GDP growth, benign credit conditions, rising interest rates and a deregulatory focus. We have lowered our 3Q18 EPS...

Barry MacCarthy
  • Barry MacCarthy

EPS cut on further hydraulic fracturing slowdown

We cut EPS forecasts (e.g. FY19 by 12%) following HAL's downbeat outlook for near-term onshore US fraccing, its second bearish guide in three months. We forecast a 17% peak to trough decline in US fracc crews, with HAL revenues declining by a proportionate amount. We see a H219 pick-up as E&Ps gear up to fill new oil pipelines from the Permian. We remain Neutral with a $44 price target (from $45).

Sam Hudson ... (+2)
  • Sam Hudson
  • CFA

Model Update

AZO's Q4 comp proved modestly disappointing, considering the current industry momentum, with company-specific challenges weighing on sales in the middle of the quarter. We estimate that online promotional shifts and out-of-stock issues impacted comps by 60-80bps. We believe the broader backdrop remains robust however, with stronger trends as AZO exited the quarter, but view ORLY/AAP as better positioned to capitalise on these trends. We remain Neutral on AZO.

Daniela Nedialkova ... (+2)
  • Daniela Nedialkova
  • CFA

Strong Q1, faster than expected recovery in NA

Nike reported Q1 EPS of $0.67 vs consensus $0.63 with in-line revenues. It was a strong quarter, delivering on the promised revenue and margin acceleration and indicating further trend strengthening. The stock was off 4% after hours, as it is difficult to beat the very high expectations, but Nike should remain a core investment on brand momentum and growth opportunities across all lines of business.

John Heagerty ... (+3)
  • John Heagerty
  • Nadja Heini
  • CFA

Financials: structural & cyclical drivers remain positive

Within financials we are positive on the banks, life insurers and insurance brokers. Valuations remain appealing, particularly for the life insurers, and cyclical drivers, such as strong equity markets, rising rates and improving GDP growth are favourable. We are more cautious on the P&C sub-sector, given the excess capital in the industry, as well as the ratings agencies due to valuation. Our top picks within financials are C, GS, MET and AON.

Richard Radbourne
  • Richard Radbourne

Higher Valuation Should Follow Spins

We expect HON to follow H118 with another strong performance in H218, while at the same time complete the planned spins of its turbo and home security products/distribution businesses. We believe the spins should lead to a stronger valuation for the ongoing HON portfolio and reiterate our Overweight rating.

Daniela Nedialkova ... (+2)
  • Daniela Nedialkova
  • CFA

Updating estimates post Q2

We are updating our estimates post Q2, reflecting new guidance as well as changes in accounting for gross margin. Our estimate for FY18 EPS is $4.04, within the guidance range $3.95 - $4.15.

Edward Lewis
  • Edward Lewis

US HPC - Initiating Coverage: O/W: EL, CHD & PG; N: CLX & CL; U/W: KMB

For many years, the Household Products and Personal Care (HPC) sector offered attractive long term growth providing products that address the daily needs of millions of consumers around the world. Underlying mid-single digit category growth was supported by innovation, pricing, acquisitions and geographic expansion to support attractive high single digit sales growth which saw the sector earn a premium valuation. However, the growth profile is not what it once was and the sector's valuation has ...

Barry MacCarthy
  • Barry MacCarthy

Remain Overweight despite slow international recovery

A recovery in International E&P activity has been frustratingly slow, with higher costs than we had assumed, which we reflect in our reduced earnings forecasts. However, a recovery is finally underway and is broadening across key regions, supported by favorable oil prices, a cumulative deficit in spending and a falling inventory of ready-to-produce volumes held by S&P Energy stocks. Despite poor YTD share-price performance (-9%), we argue it is the wrong time to turn pessimistic on SLB. Accordin...

Daniela Nedialkova ... (+2)
  • Daniela Nedialkova
  • CFA

Strong turnaround, looking for an opportunity

Having recently met with management, we have high confidence in the turnaround at the brand and the long-term targets set at the recent investor day. The foundation for strong and healthy growth has been set and we see a good chance for incremental upside to targets. Valuation and a likely quieter Fall season keep us Neutral for now, and we are looking for a better buying opportunity for what we see is a high quality, long-term, branded growth story.

John Heagerty ... (+3)
  • John Heagerty
  • Nadja Heini
  • CFA

Deal highly EPS accretive, but some concerns

MMC today announced the acquisition of Jardine Lloyd Thompson (JLT) for $6.4bn at a 34% premium to yesterday's close. The deal should complete in spring 2019 and be immediately accretive to cash EPS. The EV/EBITDA multiple of 19.5x looks expensive but moderates to a justifiable 11x when taking the full targeted cost synergies into account. We calculate that the transaction will be 9% accretive to adjusted cash EPS in 2021 but this moderates to 4% accretion if the buyback is cancelled for two yea...

Steve Chesney
  • Steve Chesney

Alopecia data tees up potential blockbuster

PFE presented the first proof-of-concept data for two JAK inhibitors in the treatment of alopecia areata. While still early, initial efficacy and safety data are encouraging. PFE is in the lead in this potential multi-$b indication and these data further support its aim of launching 15 blockbusters over the next five years.

Kunaal Malde ... (+2)
  • Kunaal Malde
  • CFA

ATVI/EA: update on core IP and key growth drivers

Activision's upcoming CoD introduces a battle royale mode that should expand the game's addressable market, while the company has several continuing growth drivers across mobile, MTX and advertising. We increase our YE PT to $85. Conversely, we trim our EA PT to $140 due to execution issues and the Battlefield related guidance cut. But we remain Overweight given the ongoing digital tailwinds and continue to expect re-acceleration of FIFA Ultimate Team.

Steve Chesney
  • Steve Chesney

Pharma review offers few material updates

JNJ's pharma business review reiterated the aim to grow above the market via additional indications, Actelion and up to 10 blockbuster launches by FY2021. We see a mix of successes and setbacks for the JNJ pipeline over the last two years and continue to question whether the pipeline is enough to offset rising generic/biosimilar and innovative competition. Maintain Underweight.

John Heagerty ... (+3)
  • John Heagerty
  • Nadja Heini
  • CFA

Executing well, remains undervalued

Citigroup has announced an increase in its financial targets with the most important being the 50bp increase in its 2020 RoTCE target to 13.5%. As part of this, management also provided a clearer pathway to an efficiency ratio of 53% in 2020, implying ~200bp of improvement in 2019 and 2020. This is considerably faster than the market anticipated. We have adjusted our forecasts such that we reach a ratio of 54.0% in 2020. This adds ~1.5% to our FY19 EPS and ~3% to our FY20 EPS while leaving room ...

James Cordwell
  • James Cordwell

New iPhones test pricing power

With its new iPhone line up Apple has pushed pricing higher, highlighting how it is increasingly reliant on ASP to deliver revenue growth. Evidence to date that iPhone demand is relatively inelastic suggests Apple should be able to drive through these price increases, but with the feature differential across the portfolio arguably narrowing as the spread in prices simultaneously widens, we do see a risk that consumers will trade down to lower tier devices. Combined with a multi-year high PE, we ...

Steve Chesney
  • Steve Chesney

Filgotinib RA data an incremental positive

FIrst Phase III data filgotinib in RA patients looks solid and while not necessarily significantly differentiated on efficacy, the safety profile could be an advantage vs other JAK inhibitors in development. We await further clinical updates including Ph III RA and Crohn's data in 2019 as well the MANTA trial looking at potential filgotinib toxicity in males. We revise up probability of success in RA to 80% and increase peak sales estimate to $2.1b from $1.7b and increase our DCF-derived target ...

John Heagerty ... (+3)
  • John Heagerty
  • Nadja Heini
  • CFA

Modest capital raise, as expected

FRC announced its first share offering of the year and is set to raise 2.0-2.3m shares in a range of $101-103, which should raise $200-240m. We were already forecasting a capital raise of 2.0m shares this quarter so the impact on our forecasts is minimal. If management exercises the greenshoe then the additional 0.3m shares will be 0.2% dilutive to our FY19 EPS but 0.2% accretive to BVPS. The share offering is priced at around 2.2x 2018E BV and 18.5x 2019E EPS. The capital injection will boost t...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch